LOXAM/JCDECAUX
28.3.2017 16:42:10 CEST | Business Wire | Press release
In 2017, LOXAM, the European leader in the rental of equipment and tooling for building, public works and industry, is celebrating its 50th anniversary. In association with JCDecaux Artvertising, a vast fresco produced by the agency SuperCafard has been installed on the glass façade of its Group Headquarters at Porte Maillot, Paris. Spanning almost 500 square metres, this specially-created visual represents the vitality that has been the Group’s hallmark over the past 50 years.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170328006023/en/
This year LOXAM is celebrating its 50th , and is keen to tell the world. Founded in Brittany in 1967, the Group is today the European number one in equipment rental. This outstanding achievement is shared by the 7,500 employees in the company today, spread over 21 countries around the world. To produce and deploy a visual in keeping with the scale of the event, LOXAM selected the agency SuperCafard to design the graphics, and JCDecaux Artvertising – its long-standing partner in temporary display advertising – for the installation of the decal on the façade of its Paris offices.
Capitalising on the expertise and experience of the teams at JCDecaux Artvertising, the decal measuring nearly 500 square metres was installed in the space of three days by six abseilers. Five spotlights are trained on this visual, which will now be visible to more than 50,000 vehicles per day passing through the Place de la Porte Maillot between now and the end of June.
An exceptional anniversary deserves exceptional visibility at LOXAM!
About :
JCDecaux Artvertising
With prestigious and strategically-located locations, the full range of JCDecaux Artvertising’s special-build decal solutions provides brands with powerful assets with which to promote their image.
LOXAM
Loxam is the market leader in the rental of equipment and tooling for
building, public works and industry, with pro forma turnover of 1.3
billion euros in 2016 and a workforce of 7,500 employees. The Group
operates out of 21 countries around the world.
www.loxam.com
SuperCafard
SuperCafard, an independently-owned design agency, is proud to support LOXAM in a BIG celebration. For the 50th anniversary of the equipment rental company, SuperCafard thought big by recommending a visual on the scale of a major brand. Just like LOXAM, we are not afraid to magnify major projects, and we will always find the means to embody them.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170328006023/en/
Contact:
LOXAM press contact
Yannick DUVERGE,
Tel.: +33 6
89 44 64 07
yannick@relationpresse.com
or
JCDecaux
product communication press contact
Xavier GUEPET,
Tel.:
+33 1 30 79 34 48
xavier.guepet@jcdecaux.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Teamily AI Reports 32× Quarterly User Growth, Positive Gross Margins, and Strong Global Adoption of Human–Agent Collaboration3.11.2026 14:00:00 CET | Press release
The AI-native collaboration platform reaches 320,000 users across 100+ countries, validates product-led growth and monetization, and prepares to expand its global AI agent ecosystem. Teamily AI, a human–agent collaboration platform that enables people and AI agents to work together in a unified, context-aware workspace, today announced significant growth and commercial milestones following a quarter of rapid global expansion. The company grew from 10,000 to 320,000 sign-ups in a single quarter, a 32× increase that works out to a compound monthly growth rate of 217.5%, just three months after its public launch in July 2026. With positive gross margins on paying users, and growing adoption among professional teams and businesses, Teamily AI establishes a foundation for scalable product-led growth (PLG). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103047955/en/ 32× Global Growth in One Quarter Teamily AI grew from 10,000
Fourthline and Veridas Complete Merger to Create a European Leader in Bank-Grade Digital Identity3.11.2026 13:40:00 CET | Press release
One provider for identity, compliance and fraud prevention across 50+ countries, with a single integrated platform. Fourthline and Veridas combined will create a global bank-grade identity platform: sovereign AI, modular compliance, and proprietary anti-fraud and biometric technology across Europe, Latin America, and the US; on track for 200 million verifications in 2026. With a projected combined revenue of more than €50m in 2026 and both businesses EBITDA-positive at closing, the company expects to reach €85m annual recurring revenue in 2029. Financials: The transaction includes funding of up to €65m provided by existing shareholder Finch Capital, new equity investment from Seaya Andromeda and debt financing from Ashgrove Capital. Fourthline and Veridas today announce the completion of their merger, first announced on 16 July 2026. The transaction closed on 3 November 2026 following the satisfaction of all closing conditions. This press release features multimedia. View the full rele
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights3.11.2026 12:30:00 CET | Press release
Final NDA submission nearing completion and will be filed in the next two weeks Launch readiness on track for expected launch in H12027, subject to FDA approval Data from two positive Phase 3 trials reinforce COMP360's unique and highly differentiated profile of rapid onset and durability of effect with 52-week open label data from COMP005 showing notable added benefit from an additional COMP360 25 mg dose extending durability out to one year The Phase 3 data supports the belief that COMP360 has the potential to establish a new standard of care in TRD that can be life-changing for patients − moving beyond daily or frequent administration toward an option that could provide durable benefit with just a few treatments a year COMP360 expected to be a blockbuster opportunity with an estimated 4 million people in the U.S. living with TRD, a significantly underserved market where the only marketed medicine has captured <3% market share COMP360 expected to fit seamlessly into current treatment
Vedanta Limited Delivers Highest-ever Half-yearly Profit of $1.21 bn, up 151% YoY3.11.2026 12:26:00 CET | Press release
Indian multinational Vedanta Limited (BSE: 500295 & NSE: VEDL), a global leader in metals and critical minerals, announced its consolidated results for the second quarter and half year ended 30 September 2026, delivering its best-ever financial performance driven by operational excellence and disciplined execution. Vedanta Limited achieved its highest-ever quarterly Profit of $649 mn, up 151% YoY, while half-yearly Profit reached a record $1.21 bn, up 151% YoY. Vedanta also declared its first interim dividend of INR 5 per share during the quarter, reinforcing its commitment to shareholder returns. The Company delivered record quarterly revenue of $2.70 bn, up 57% YoY, taking half-yearly revenue to a record $5.18 bn, up 54% YoY. Quarterly EBITDA surged 106% YoY to $1.04 bn, while half-yearly EBITDA reached a record $1.94 bn, up 103% YoY. EBITDA margins expanded to 60% in Q2 and 58% in H1, improving by 1,055 bps and 1,023 bps YoY, respectively. Vedanta further strengthened its balance sh
BeOne Medicines to Present at the Jefferies Global Healthcare Conference3.11.2026 12:01:00 CET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, with a fireside chat at 9:30 a.m. GMT. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
